First Sound Pharmaceuticals has welcomed two key products in the third quarter through the HKEx hearing

According to the announcement of the Hong Kong Stock Exchange, Sonic Pharmaceuticals has recently been heard through the Hong Kong Stock Exchange.
submitted an IPO application on the Hong Kong Stock Exchange in June this year, in accordance with Article 8.12 of the Listing Rules.
according to the hearing information set, the funds raised at HKEx will be used in part for the ongoing research and development of selected products in the field of oncology and the central nervous system.
it's worth noting that in the third quarter of this year, the acoustics industry welcomed two key products, Idala's rightol injection with a strong solution and a basip.
Screenshot Source: Resources: Synth Pharmaceuticals is a pharmaceutical company that is rapidly transforming into an innovation and research and development driver, dedicated to making more effective drugs available to patients at an early time.
2000, the First Sound New Drug Research Center was established.
in 2003, the First Sound Pharmaceutical Research Institute was established, and in 2018, the First Sound Pharmaceutical Innovation Center was established.
the company focuses on three fast-growing therapeutic areas with significant unsuperped medical needs, including tumors, central nervous system diseases, and autoimmune diseases.
based on public information on the synth pharmaceutical industry, it now has more than 50 product portfolios, most of which have entered the national health insurance and national essential medicines catalogue.
has ushered in key products in the listed products, class 1 innovative drug Endemic (recombinant human endodermic inhibitor injection), is one of the earliest listed antivascular targeted drugs in China.
autoimmune disease treatment drug Edsin (Iramod tablets) has been recommended by several guidelines as the main treatment for active rheumatoid arthritis.
two new drugs have been added to the National Health Insurance Drug List since 2017.
the third quarter of this year, the first sound medicine industry ushered in two key products.
including the company after 13 years of independent research and development of independent intellectual property rights of a class 1 innovative drug Ida la feng rightalcohol injection with a thick solution, through the priority review process approved in China, adaptive patients.
another A basip injection developed for BMS, which was officially launched in China in August for rheumatoid arthritis.
this is a soluble fusion protein formed by the fusion of human cytotoxic T lymphocyte-related antigen 4 (CTLA-4) extracellular region with human IgG1Fc region.
2013, BMS reached a strategic partnership with Synth Pharmaceuticals to develop Abaazyth in China.
addition, according to the hearing data set, the recent acoustic pharmaceutical industry is also expected to usher in a subdermal injection of PD-L1 single anti-KN035 (envafolimab).
March 2020, Synth Pharmaceuticals signed a cooperation agreement with Jiangsu Corning Jerry and Beijing Yidi Pharmaceuticals, which grants Synsheng Pharmaceuticals exclusive rights to market and promote KN035 in All Tumor Adaptations in China.
, the product is currently in Phase 2 clinical trials for colorectal and other advanced solid tumors and Phase 3 clinical trials for advanced bilibroid cancer, which are expected to be approved for market in 2021.
it is worth mentioning that the product was included in the priority review list in China in September this year on the grounds that it "meets the conditions for approval".